News | October 31, 2022
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Subscribe To Our Newsletter & Stay Updated
